실적분석 2026년 8월 3일

Vertex Pharmaceuticals ($VRTX) Q2 2026 Earnings Analysis — Revenue Beats, Full-Year Guidance Raised; Adjusted EPS Slightly Misses

Earnings Scorecard

Revenue: $3.334 billion (+12% YoY, estimate $3.225 billion) ✅ Beat

EPS: Adjusted diluted $4.73 (estimate $4.75) ❌ Miss

Guidance: Raised — 2026 full-year revenue $13.1–$13.2 billion (prior $12.95–$13.1 billion)

Stock Reaction: After-hours -0.37% ($469) — as of 08-04 07:01 KST

Positives

Revenue earnings surprise: Q2 revenue of $3.334 billion beat the $3.225 billion estimate

Strong growth in non-cystic fibrosis products: CASGEVY $76.4M, JOURNAVX roughly $50M

Full-year revenue guidance raised: Lifted to $13.1–$13.2 billion from prior range

Vertex Pharmaceuticals' ($VRTX) total Q2 2026 revenue reached $3.334 billion, up 12% from $2.965 billion a year earlier and above the $3.225 billion consensus. U.S. revenue was $2.06 billion (+11%) and ex-U.S. revenue was $1.28 billion (+14%), with the expansion of ALYFTREK and favorable FX effects supporting international growth.

By product, the cystic fibrosis portfolio remains the core franchise, but diversification is clearly visible. CASGEVY, a gene-editing therapy, generated $76.4 million in revenue, up 78% quarter-over-quarter and 151% year-over-year, while JOURNAVX, a non-opioid acute pain treatment, brought in $49.6 million, more than quadrupling from $12 million a year earlier. The company raised its full-year revenue outlook to $13.1–$13.2 billion, and said it expects more than $500 million in revenue from non-cystic fibrosis products (CASGEVY and JOURNAVX).

Negatives

Slight adjusted EPS miss: Adjusted diluted $4.73 fell short of the $4.75 estimate

TRIKAFTA revenue decline: Down roughly 2% YoY, making the pace of next-generation transition a key question

Higher costs and a large acquisition as variables: Rising SG&A and R&D; the Crinetics acquisition is not yet reflected in guidance

Adjusted (non-GAAP) diluted EPS was $4.73, coming in 2 cents below the $4.75 analyst estimate. Because consensus is on an adjusted basis, this should not be compared directly with GAAP diluted EPS of $4.31. GAAP net income for Q2 2026 was $1.0998 billion, up from $1.0329 billion a year earlier, while adjusted net income was $1.2073 billion.

Lead product TRIKAFTA generated $2.497 billion in revenue, down from $2.551 billion a year ago, reflecting the ongoing patient transition to ALYFTREK. At the same time, the JOURNAVX launch and build-out of the renal franchise have pushed R&D and SG&A higher, and the roughly $10 billion Crinetics Pharmaceuticals acquisition is expected to close in Q3 2026 but is not yet reflected in current guidance, leaving room for a guidance revision after closing.

What Management Said

Management characterized the quarter as one of expanding cystic-fibrosis leadership, growing revenue in sickle cell disease, beta thalassemia, and acute pain, and adding a fifth therapeutic pillar in rare endocrine diseases through portfolio diversification. Even as it raised full-year revenue guidance, the company kept its R&D and SG&A expense guidance as well as its non-cystic fibrosis product revenue target (more than $500 million) unchanged, striking a tone of balancing growth with cost discipline.

On the pipeline, management highlighted the November 30, 2026 target action date for U.S. approval of povetacicept, an IgA nephropathy treatment, and drew a clear line that updated guidance will be provided after the Crinetics acquisition closes. The overall message was a commitment to advancing both commercial product expansion and the next-generation pipeline in parallel.

Market Reaction and What to Watch Next

Despite the revenue beat and the full-year guidance raise, the market reaction was muted. With adjusted EPS slightly below estimates and higher costs and a major acquisition (not yet in guidance) read as near-term uncertainties, the print, while solid, did not deliver a clean "better than expected across the board" setup.

Monitor whether the U.S. review and launch readiness for povetacicept (target action date November 30, 2026) stays on track.

Watch the timing of the Crinetics acquisition close and how acquisition costs and revenue are reflected in post-close revised guidance.

Track the sequential ramp of CASGEVY and JOURNAVX and whether the full-year target of more than $500 million in non-cystic fibrosis product revenue is achieved.